

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Meeting #8

Shelly Spiro, Co-Chair

Hans Buitendijk, Co-Chair

August 23, 2023



Call to Order/Roll Call

Mike Berry, Designated Federal Officer, ONC

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster

Name	Organization	Name	Organization
Hans Buitendijk* (Co-Chair)	Oracle Health	Shelly Spiro (Co-Chair)	Pharmacy HIT Collaborative
Pooja Babbrah	Point-of-Care Partners	Deven McGraw*	Invitae Corporation
Chris Blackley	Prescryptive	Ketan Mehta	Micro Merchant Systems
Shila Blend*	North Dakota Health Information Network	Justin Neal	Noble Health Services
David Butler	Curatro, LLC	Eliel Oliveira*	Dell Medical School, University of Texas at Austin
Steven Eichner*	Texas Department of State Health Services	Naresh Sundar Rajan*	CyncHealth
Rajesh Godavarthi*	MCG Health, part of the Hearst Health network	Scott Robertson	Bear Health Tech Consulting
Adi V. Gundlapalli**	Centers for Disease Control and Prevention	Alexis Snyder*	Individual
Jim Jirjis*	HCA Healthcare	Fillipe Southerland*	Yardi Systems, Inc.
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Community Pharmacy Owner
Steven Lane*	Health Gorilla	Sheryl Turney*	Elevance Health
Meg Marshall**	Department of Veterans Health Affairs	Afton Wagner	Walgreens
Anna McCollister*	Individual		



12:00 PM

10:30 AM	Call to Order/Roll Call			
	Mike Berry, Designated Federal Officer, ONC			
10:35 AM	Opening Remarks			
	Shelly Spiro, Co-Chair			
	Hans Buitendijk, Co-Chair			
10:40 AM	Task 2b Use Case Review and 2c Recommendation Discussion			
	Hans Buitendijk, Co-Chair			
10:55 AM	Task 2d Introduction: What can ONC do to address drug inventory transparency to prescribers and consumers?			
	Shelly Spiro, Co-Chair			
11:00 AM	Guest Presentation			
	 Phillip Lettrich, RPh, Health Policy and Business Development – Vela 			
11:05 AM	Task 2d Discussion			
	Shelly Spiro, Co-Chair			
	Hans Buitendijk, Co-Chair			
11:50 AM	Public Comment			
	Mike Berry, Designated Federal Officer, ONC			
11:55 AM	Task Force Work Planning			

Shelly Spiro, Co-Chair

Adjourn



Opening Remarks

Shelly Spiro, Co-Chair

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

Overarching charge: Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

Recommendations Due: November 9, 2023

Specific charge:

- 1. Public Health, Emergency Use Authorizations, and Prescribing Authorities
- 2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
- 3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
- 4. Identify policy and technology needs and considerations for direct-to-consumer medication services.

Supporting Clinical Pharmacy Services and Coordinated Care

TASK 2: July 26- August 23

- 2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
 - a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
 - b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
 - c. What technology gaps exist for pharmacists to participate in value-based care?
 - d. What can ONC do to address drug inventory transparency for prescribers and consumers?

Task 2b Use Case Review and 2c Recommendation Discussion



Task 2d Introduction: What can ONC do to address drug inventory transparency for prescribers and consumers?

Shelly Spiro, Co-Chair

Guest Presentation

Phillip Lettrich, RPh, Health Policy and Business Development – Vela

Task 2d Discussion

Shelly Spiro, Co-Chair

Task 2: Supporting Clinical Pharmacy Services and Coordinated Care

- 2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
 - a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
 - b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
 - c. What technology gaps exist for pharmacists to participate in value-based care?
 - d. What can ONC do to address drug inventory transparency for prescribers and consumers?



To make a comment please Use the Hand Raise Function

If you are on the phone only, press "*9" to raise your hand

(Once called upon, press "*6" to mute/unmute your line)

All public comments will be limited to three minutes

You may also email your public comment to onc-hitac@accelsolutionsllc.com

Written comments will not be read at this time, but they will be delivered to members of the task force and made part of the public record

Task Force Work Planning

Shelly Spiro, Co-Chair

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

Overarching charge: Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

Recommendations Due: November 9, 2023

Specific charge:

- 1. Public Health, Emergency Use Authorizations, and Prescribing Authorities
- 2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
- 3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
- 4. Identify policy and technology needs and considerations for direct-to-consumer medication services.

Upcoming Meetings

Month	Task Force Meeting Dates	HITAC Meeting Date
August	30	
September	13, 20, 27	September 14 (TF Update)
October	4, 11, 18, 25	October 19 (TF Update)
November	1	November 9 (Final Recommendation and Vote)

Adjourn